FeldblyumTV, SegalDM. Seasonal and pandemic influenza surveillance and disease severity. In: ShapshakP, SinnottJT, SomboonwitC, KuhnJH, eds. Global Virology I - Identifying and Investigating Viral Diseases. New York: Springer; 2015:761-789.
15.
US Centers for Disease Control and Prevention. What is syndromic surveillance? Last reviewed September 20, 2023. Accessed January5, 2024. https://www.cdc.gov/nssp/overview.html
GronvallGK, MathenyJ, SmithBT, et al.Flexible defenses roundtable meeting: promoting the strategic innovation of medical countermeasures. Biosecur Bioterror. 2007; 5(3):271-277.
28.
National Research Council. Sequence-Based Classification of Select Agents: A Brighter Line. Washington, DC: The National Academies Press; 2010:21-35. Accessed January5, 2024. https://doi.org/10.17226/12970
29.
SimpsonS, KaufmannMC, GlozmanV, ChakrabartiA. Disease X: accelerating the development of medical countermeasures for the next pandemic. Lancet Infect Dis. 2020; 20(5):e108-e115. Published correction appears in Lancet Infect Dis. 2020;20(12):e298.
30.
O'LearyCN, Barnes-WeiseJ, HoytK, BourdeauxM. Maintaining warp speed: policy requirements for a just-in-time, capability-based, scalable medical countermeasure research and development enterprise. Health Secur. 2023; 21(4):272-279.
Administration for Strategic Preparedness and Response (ASPR). ASPR awards $21 million to health facilities to enhance nations preparedness for special pathogens. Published October 24, 2022. Accessed January5, 2024. https://aspr.hhs.gov/newsroom/Pages/RESPTC-Prep-Award-24Oct2022.aspx
33.
MukherjeeV, SauerLM, MehtaAK, et al.The evolution of the national special pathogen system of care. Health Secur. 2022; 20(suppl 1):S39-S48.
34.
AndonianJ, GalushaKE, MaragakisLL, GaribaldiBT. The impact of high-level isolation units beyond high-consequence pathogen preparedness. Health Secur. 2019; 17(1):69-73.
35.
SlaouiM, HepburnM. Developing safe and effective Covid vaccines - Operation Warp Speed's strategy and approach. N Engl J Med. 2020; 383(18):1701-1703.
36.
KimJH, HotezP, BatistaC, et al.Operation Warp Speed: implications for global vaccine security. Lancet Glob Health. 2021; 9(7):e1017-e1021.
37.
Office of the Assistant Secretary for Preparedness and Response. Addressing New Variants: A Federal Perspective on the COVID-19 Response. Testimony before the Senate Committee on Health, Education, Labor, and Pensions. January11, 2022. Accessed January8, 2024. https://www.help.senate.gov/imo/media/doc/O%27Connell3.pdf
38.
US Department of Health and Human Services (HHS). Public Health and Social Services Emergency Fund (FY 23): Justification of Estimates for Appropriations Committee. Washington, DC: HHS; 2023. Accessed January8, 2024. https://www.hhs.gov/sites/default/files/fy-2023-phssef-cj.pdf
US Government Accountability Office (GAO). Biological Defense: DOD Has Strengthened Coordination on Medical Countermeasures But Can Improve Its Process for Threat Prioritization. Washington, DC: GAO; 2014. Accessed January8, 2024. https://www.gao.gov/assets/gao-14-442.pdf
41.
US Department of Defense. 2017 Annual Report to Congress. Washington, DC: Department of Defense Publishing, 2017:1-4. Accessed August29, 2023https://irp.fas.org/threat/cbw/cbd-2017.pdf
42.
LeiserOP, HobbsEC, SimsAC, KorchGW, TaylorKL. Beyond the list: bioagent-agnostic signatures could enable a more flexible and resilient biodefense posture than an approach based on priority agent lists alone. Pathogens. 2021; 10(11):1497.
National Academies of Sciences, Engineering, and Medicine. A Proposed Framework for Identifying Potential Biodefense Vulnerabilities Posed by Synthetic Biology: Interim Report. Washington, DC: The National Academies Press; 2017. Accessed January8, 2024. https://nap.nationalacademies.org/read/24832/chapter/2
The Small Business Innovation Research and Small Business Technology Transfer Programs. A step towards agent agnostic detection of biological hazards. Release date: November 16, 2021. Accessed January8, 2024. https://www.sbir.gov/node/2100473
50.
SheaDA, ListerSA. The Biowatch Program: Detection of Bioterrorism. Congressional Research Service Report No. RL 32152. Washington, DC: Congressional Research Service; 2003. Accessed January8, 2024. https://sgp.fas.org/crs/terror/RL32152.html
51.
SmolinskiMS, CrawleyAW, OlsenJM. Finding outbreaks faster. Health Secur. 2017; 15(2):215-220.
52.
KorchG.Evolution on thoughts for host-based therapeutic approaches to current and future threats. Presented at: Pacific Northwest National Laboratory Advancing Threat Agnostic Biodefense Webinar Series; February 16, 2023. Accessed January8, 2024. https://www.pnnl.gov/advancing-threat-agnostic-biodefense-webinar-series
53.
OkinakaR, PearsonT, KeimP. Anthrax, but not Bacillus anthracis?. PLoS Pathog. 2006; 2(11):e122.